QualityStocks'  Instablog

Biotech small-cap Advaxis has been nominated for the Vaccine Industry Excellence (ViE) Award sponsored by Novartis Vaccines and Diagnostics. The ViE award recognizes companies and individuals that have demonstrated influential accomplishments and contributions to the vaccine industry within the prior 12 months.

Nominees are selected according to criteria such as the company's ability to advance their business from early stage to mature, create a quality and diverse pipeline, achieve clinical advancements, establish significant partnerships, and successfully secure funds for continued growth.

Advaxis chairman and CEO Thomas A. Moore detailed the company's initiatives leading up to its second straight nomination for the ViE award.

"We are delighted to be nominated in two consecutive years for a ViE award," Moore stated in the press release. "In 2012, we made tremendous progress advancing our lead program in the clinic and achieved proof-of-concept of ADXS-HPV in the indication of cervical cancer. Our mission is to continue to set the foundation to become the industry leader in immunotherapy drug development and HPV-associated cancer research. The nomination for Best Early-Stage Vaccine Biotech validates the company's research and clinical development over the past year."

The winner will be announced April 17, 2013, at the 6th annual ViE Awards Ceremony & Gala Dinner held in conjunction with the 13th Annual World Vaccines and Expo Conference to be held April 16-18 in Washington, DC.

For more information, please visit advaxis.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net